Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$830.39 USD

830.39
342,620

+13.74 (1.68%)

Updated Nov 7, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Why Regeneron (REGN) Might Surprise This Earnings Season

Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Shaun Pruitt headshot

Time to Buy Cigna or Regeneron Stock Before Earnings?

Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Sanofi (SNY) Keep the Beat Streak Alive in Q4 Earnings?

Sanofi's (SNY) top line is likely to have been driven by higher sales of Dupixent and vaccines.

Regeneron (REGN) Stock Moves -0.86%: What You Should Know

Regeneron (REGN) closed the most recent trading day at $736.46, moving -0.86% from the previous trading session.

Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.

Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Gains But Lags Market: What You Should Know

Regeneron (REGN) closed the most recent trading day at $729.91, moving +1.1% from the previous trading session.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know

Regeneron (REGN) closed the most recent trading day at $714.57, moving +0.65% from the previous trading session.

REGN or TECH: Which Is the Better Value Stock Right Now?

REGN vs. TECH: Which Stock Is the Better Value Option?

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update

Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.

Company News for Jan 10, 2023

Companies In The News Are: REGN, LULU, DCT, BAX.

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

VERA Dips Despite Positive Data From IgA Nephropathy Study

VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.

What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?

Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

Style Box ETF report for SPGP

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma

Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma.

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

Smart Beta ETF report for GSEW

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth

Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline. However, pipeline setbacks remain concerning.